WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 07/27/22

Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would jump as much as 37%. The provider of outsourced pharmaceutical services has delivered on bullish market hopes of ...

WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore PR Newswire This investment will establish a cutting-edge, fully integrated CRDMO center in Singapore , including a research and development service center and large-scale drug substance and dr...

Pfizer ( NYSE: PFE ) backed Chinese cancer drugmaker CStone Pharmaceuticals ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company, Bloomberg News reported citing people with knowledge of the matter. WuXi Healthcare Ventures, a unit of...

WuXi Vaccines said it received a GMP (Good Manufacturing Practice) certificate from Ireland Health Products Regulatory Authority for its QC potency lab in Dundalk, Ireland. WuXi Vaccines, which is a joint venture between WuXi Biologics ( OTCPK:WXXWY ) and Shanghai Hil...

Contract manufacturing organization WuXi XDC, a joint venture between WuXi Biologics ( OTCPK:WXXWY ) and WuXi STA, is collaborating with South Korean antibody-drug conjugates (ADC) maker AbTis. Under the agreement, AbTis will use WuXi XDC's integrated services fo...

WuXi Biologics ( OTCPK:WXXWY ) ( OTCPK:WXIBF ) gained nearly 12% on Tuesday after Reuters reported that the Wuxi, China-based life sciences company is one step closer to getting off the U.S. Commerce Department's "Unverified List." According to a department official, C...

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes PR Newswire WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (...

We had previously owned WuXi Biologic shares but sold it in the second quarter of 2019. We bought back WXIBF stock after a sharp price correction in the first quarter of 2021. The rapid development of several antibody drugs for COVID-19 gave a further, unexpected boost to WuXi...

Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989. Stock markets fell in the quarter, as the world watched in horror Russia’s invasion of Ukraine. China-based WuXi Biologics illustrates the perf...

Vir Biotechnology (NASDAQ:VIR) announced on Friday that its Chinese partner WuXi Biologics (OTCPK:WXXWY) (OTCPK:WXIBF) ended its partnership for development and manufacturing for several of company’s antibody drugs including the COVID-19 antibody therapy sotrovimab. Per the terms of th...